About Us

About Profound

Pioneering the expanded human proteome

Our team is creating profound impacts on our understanding of biology and disease and our ability to create therapeutics that would not have previously been possible.

Our Origin Story

Profoundly impacting our understanding of biology

In 2019, ProFound’s founding team of Noubar Afeyan, Avak Kahvejian, Yann Echelard, Vini Mani, and Erica Weinstein were inspired by a belief that there existed “proteomic dark matter” – peptides and proteins – that could potentially be detected but had thus far gone unannotated and ignored, along with aberrations in the human genome that play unexplained roles in disease. Hypothesizing that there must be a link, we began to explore the white space of proteomics. Our team unearthed several observations, among them that small, functional proteins seemed to be emerging from what were believed to be non-coding lncRNA transcripts in humans. This surprising insight led the team to ask, “What if the ability of so-called ‘non-coding’ RNAs to create functional proteins was a universal phenomenon and not an exception?” If that were true, it would have profound impacts on our understanding of biology and disease and our ability to create therapeutics that would not have previously been possible.

It turned out that this was precisely the case. In developing tools to reveal the compendium of sequences that are translated into proteins, the team created the ProFoundry™ Atlas, an expanse of at least tens of thousands of novel protein sequences across human biology, each with the potential to be a critical intervention point in disease. Using systematic, hypothesis-driven interrogation of the Atlas, combined with advanced computation and targeted functional screening, ProFound™ Therapeutics has started to reveal previously unknown genetic drivers of disease, immune modulators, circulating metabolic factors, and more. All of these discoveries will feed a diverse pipeline of revolutionary new medicines. This new biology has now opened a vast frontier, with the grand vision to unleash multiples of the biotechnology industry.

Founding Team

Avak Kahvejian, Ph.D.
Founding CEO
General Partner, Flagship Pioneering
Vini Mani, Ph.D.
Head of Platform
Senior Associate, Flagship Pioneering
Erica Weinstein, Ph.D.
Head of Research
Principal, Flagship Pioneering
Kala Subramanian, Ph.D.
President
Operating Partner, Flagship Pioneering
Yann Echelard, Ph.D.
Advisor
Operating Partner, Flagship Pioneering
Noubar Afeyan, Ph.D.
Chairman
Founder & CEO, Flagship Pioneering
Charlotte Nicod
Proteomics Advisor
Associate, Flagship Pioneering

Scientific Advisory Board

Ruedi Aebersold, Ph.D.
Emeritus Professor, Institute of Molecular Systems Biology, ETH Zurich, Switzerland
Morris Birnbaum, M.D., Ph.D.
Editorial Board Member, Science Signaling and Cell Metabolism
Anne-Ruxandra Carvunis, Ph.D.
Associate Professor, Department of Computational and Systems Biology, University of Pittsburgh School of Medicine
Mike MacCoss, Ph.D.
Professor, MacCoss Lab of Biological Mass Spectrometry, University of Washington
Anthony Manning, Ph.D.
Principal, Manning Bio Worldwide, LLC; Board of Directors, Palatin Technologies; Founder and Chairman, Institute for Biomedical Entrepreneurship
Nahum Sonenberg, Ph.D.
James McGill Professor, Department of Biochemistry and the Rosalind and Morris Goodman Cancer Institute, McGill University

Scientific Advisory Board

Ruedi Aebersold, Ph.D.
Emeritus Professor, Institute of Molecular Systems Biology, ETH Zurich, Switzerland
Morris Birnbaum, M.D., Ph.D.
Editorial Board Member, Science Signaling and Cell Metabolism
Anne-Ruxandra Carvunis, Ph.D.
Associate Professor, Department of Computational and Systems Biology, University of Pittsburgh School of Medicine
Mike MacCoss, Ph.D.
Professor, MacCoss Lab of Biological Mass Spectrometry, University of Washington
Anthony Manning, Ph.D.
Principal, Manning Bio Worldwide, LLC; Board of Directors, Palatin Technologies; Founder and Chairman, Institute for Biomedical Entrepreneurship
Nahum Sonenberg, Ph.D.
James McGill Professor, Department of Biochemistry and the Rosalind and Morris Goodman Cancer Institute, McGill University

Join Our Team

We are leading the way in the next biotech revolution by illuminating the expanded human proteome to transform human health.

Open Positions